Dr. Ricardo Restrepo-Jaramillo, MD

Dr. Restrepo-Jaramillo practices at Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital.

Dr. Restrepo-Jaramillo's NPI, 1295994952, was assigned on June 6, 2008. Dr. Restrepo-Jaramillo graduated from Pontifical Bolivarian University in 2000. Dr. Restrepo-Jaramillo holds Florida license ME120622.

Dr. Restrepo-Jaramillo's primary practice is Tampa General Hospital, at 1 Tampa General Cir, Tampa, FL 33606 in Hillsborough County. The practice phone is (813) 844-7000.

Dr. Restrepo-Jaramillo's primary practice is Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital. Dr. Restrepo-Jaramillo is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. The medical group on file is USF Therapy Services. Dmand AI also links Dr. Restrepo-Jaramillo to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Restrepo-Jaramillo practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Restrepo-Jaramillo's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Restrepo-Jaramillo is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Restrepo-Jaramillo's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists chronic respiratory failure and pulmonary heart disease among the conditions Dr. Restrepo-Jaramillo treats.

CMS data shows 570 Medicare services from Dr. Restrepo-Jaramillo across 9 procedure codes in 2024, for 292 Medicare patients. Medicare paid $59,434 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 292 Medicare patients who saw Dr. Restrepo-Jaramillo in 2024. The largest group is 65 to 74, with 121 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 3.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Restrepo-Jaramillo's median patient age at 65, with 60% women.

In 2024, Dr. Restrepo-Jaramillo wrote 2,994 Medicare Part D claims for 218 patients. CMS names the drug for 2,825 of them, across 28 drugs with 11 or more claims each, at $22,747,243 in total drug cost. In 2023, CMS named 2,366 claims across 24 drugs.

Dr. Restrepo-Jaramillo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Restrepo-Jaramillo, published from 2018 to 2025. 2021 was the busiest year, with 3. Dr. Restrepo-Jaramillo has published most often in Pulm Circ. Dr. Restrepo-Jaramillo's most frequent co-authors are Debabrata Bandyopadhyay, MD, Zeenat Safdar, MD and Hassan Mari Alnuaimat, MD.

Dmand AI links Dr. Restrepo-Jaramillo to 7 clinical trials, 4 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Hypertension, Pulmonary, Pulmonary Arterial Hypertension and Hypertension. United Therapeutics sponsors the most, 6. Open Payments lists research payments to Dr. Restrepo-Jaramillo that name 1 trial.

CMS Open Payments shows 829 general payments to Dr. Restrepo-Jaramillo from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. United Therapeutics Corporation paid the most, $358,722. It also lists 8 research payments totaling $2,977 from 2019 to 2020, naming 1 clinical trial.

Dr. Restrepo-Jaramillo graduated from Pontifical Bolivarian University in 2000.

Dr. Restrepo-Jaramillo is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.